Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss 2021-03-10 mediabest Health News NEW YORK (Reuters Health) – Long-term glucocorticoid (GC) users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab versus oral Read more